Britain’s biotech firms now have a code of conduct designed to prevent them
from overhyping the progress of experimental drugs. Published this week by the
BioIndustry Association (BIA), the code was drafted in the wake of a damaging
scandal last year
(This Week, 4 July 1998, p 20).
From now on, companies must
have their scientific and clinical progress audited by external experts. Failure
to comply could mean expulsion from the BIA.
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
We've found a mysterious substance on Titan and Pluto
2
A quantum state that lasts forever may finally be within our grasp
3
Has the answer to life's origins been hiding in our cells all along?
4
Fully autonomous drones have killed human soldiers for the first time
5
Carl Sagan's The Demon-Haunted World is still supremely relevant today
6
Can prebiotics, probiotics or postbiotics help your ageing microbiome?
7
Faecal transplant makes the brains of old mice act young again
8
The secrets to keeping your brain sharp in old age
9
The last-ditch plan to save coral reefs from utter destruction
10
Remarkable fossils rewrite the story of how animals conquered the land
